Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study

Abstract

A higher early exposure to golimumab is associated with a better objective response in active UC patients and appears to drive the outcome at Week 6.